SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name : Mometasone Dry Powder Inhaler Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet
   Company : MSD
              Shotton Lane
              NE23 3JU  Cramlington NU - Great Britain
   Telephone : 44 1 670 59 30 00
   Telefax : 908-735-1496
   E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Reproductive toxicity, Category 1B
   Specific target organ toxicity - repeated exposure, Category 2
   Long-term (chronic) aquatic hazard, Category 1
   H360Df: May damage the unborn child. Suspected of damaging fertility.
   H373: May cause damage to organs through prolonged or repeated exposure.
   H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Hazard pictograms : 
   Signal word : Danger
   Hazard statements : H360Df May damage the unborn child. Suspected of damaging fertility.
                      H373  May cause damage to organs through prolonged or repeated exposure.
Mometasone Dry Powder Inhaler Formulation

Precautionary statements:

**Prevention:**
- P201 Obtain special instructions before use.
- P260 Do not breathe dust.
- P273 Avoid release to the environment.
- P280 Wear protective gloves/protective clothing/eye protection/face protection.

**Response:**
- P308 + P313 IF exposed or concerned: Get medical advice/attention.
- P391 Collect spillage.

Hazardous components which must be listed on the label:
- Mometasone

**2.3 Other hazards**
- Dust contact with the eyes can lead to mechanical irritation.
- Contact with dust can cause mechanical irritation or drying of the skin.
- May form explosive dust-air mixture during processing, handling or other means.

**SECTION 3: Composition/information on ingredients**

**3.2 Mixtures**

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mometasone</td>
<td>83919-23-7</td>
<td></td>
<td></td>
<td></td>
<td>Repr. 1B; H360Df STOT RE 2; H373 Aquatic Chronic 1; H410</td>
<td>&gt;= 10 - &lt; 20</td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

**SECTION 4: First aid measures**

**4.1 Description of first aid measures**

**General advice:**
- In the case of accident or if you feel unwell, seek medical advice immediately.
- When symptoms persist or in all cases of doubt seek medical advice.

**Protection of first-aiders:**
- First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment.
when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks: May damage the unborn child. Suspected of damaging fertility. May cause damage to organs through prolonged or repeated exposure.

Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-: Carbon oxides
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Mometasone Dry Powder Inhaler Formulation

Version: 2.2
Revision Date: 09/13/2019
SDS Number: 493905-00010
Date of last issue: 24.04.2019
Date of first issue: 28.01.2016

5.3 Advice for firefighters
Special protective equipment for firefighters:
In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures
Personal precautions: Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.

6.2 Environmental precautions
Environmental precautions: Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up
Methods for cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling
Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling:
- Do not get on skin or clothing.
- Do not breathe dust.
- Do not swallow.
- Avoid contact with eyes.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Keep container tightly closed.
- Minimize dust generation and accumulation.
- Keep container closed when not in use.
- Keep away from heat and sources of ignition.
- Take precautionary measures against static discharges.
- Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers:
- Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage:
- Do not store with the following product types:
  - Strong oxidizing agents
  - Organic peroxides
  - Explosives
  - Gases

7.3 Specific end use(s)

Specific use(s):
- No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mometasone</td>
<td>83919-23-7</td>
<td>TWA</td>
<td>1 µg/m³ (OEB 4)</td>
<td>Internal</td>
</tr>
<tr>
<td>Further information</td>
<td>Skin</td>
<td>Wipe limit</td>
<td>10 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>
8.2 Exposure controls

Engineering measures

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

Personal protective equipment

Eye protection

Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material

Chemical-resistant gloves

Remarks

Consider double gloving.

Skin and body protection

Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection

If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type

Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance : powder
Colour : white
Odour : No data available
Odour Threshold : No data available
pH : No data available
Melting point/freezing point : No data available
Initial boiling point and boiling range : No data available
Flash point : Not applicable
Evaporation rate : No data available
## Mometasone Dry Powder Inhaler Formulation

<table>
<thead>
<tr>
<th>Flammability (solid, gas)</th>
<th>May form explosive dust-air mixture during processing, handling or other means.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapour pressure</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative vapour density</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative density</td>
<td>No data available</td>
</tr>
<tr>
<td>Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td></td>
</tr>
<tr>
<td>Water solubility</td>
<td>No data available</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>No data available</td>
</tr>
<tr>
<td>Auto-ignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td></td>
</tr>
<tr>
<td>Viscosity, kinematic</td>
<td>No data available</td>
</tr>
<tr>
<td>Explosive properties</td>
<td>Not explosive</td>
</tr>
<tr>
<td>Oxidizing properties</td>
<td>The substance or mixture is not classified as oxidizing.</td>
</tr>
</tbody>
</table>

### 9.2 Other information
- Flammability (liquids): No data available
- Molecular weight: No data available
- Particle size: No data available

### SECTION 10: Stability and reactivity

#### 10.1 Reactivity
Not classified as a reactivity hazard.

#### 10.2 Chemical stability
Stable under normal conditions.

#### 10.3 Possibility of hazardous reactions
- Hazardous reactions: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
### 10.4 Conditions to avoid

**Conditions to avoid:**
- Heat, flames and sparks.
- Avoid dust formation.

### 10.5 Incompatible materials

**Materials to avoid:**
- Oxidizing agents

### 10.6 Hazardous decomposition products

**No hazardous decomposition products are known.**

---

### SECTION 11: Toxicological information

#### 11.1 Information on toxicological effects

**Information on likely routes of exposure:**
- Inhalation
- Skin contact
- Ingestion
- Eye contact

**Acute toxicity**

Not classified based on available information.

**Components:**

**Mometasone:**

- **Acute oral toxicity**
  - LD50 (Rat): > 2,000 mg/kg
  - LD50 (Mouse): > 2,000 mg/kg

- **Acute inhalation toxicity**
  - LC50 (Rat): > 3.3 mg/l
  - Exposure time: 4 h
  - Test atmosphere: dust/mist
  - Remarks: No mortality observed at this dose.

  - LC50 (Mouse): > 3.2 mg/l
  - Exposure time: 4 h
  - Test atmosphere: dust/mist

- **Acute toxicity (other routes of administration)**
  - LD50 (Rat): 300 mg/kg
  - Application Route: Subcutaneous
  - Symptoms: Breathing difficulties

**Skin corrosion/irritation**

Not classified based on available information.

**Components:**

**Mometasone:**

- **Species**: Rabbit
- **Result**: No skin irritation
Mometasone Dry Powder Inhaler Formulation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Mometasone:
Species: Rabbit
Result: No eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Mometasone:
Test Type: Maximisation Test
Exposure routes: Dermal
Species: Guinea pig
Assessment: Does not cause skin sensitisation.
Result: negative
Remarks: The results of a test on guinea pigs showed this substance to be a weak skin sensitiser.

Germ cell mutagenicity
Not classified based on available information.

Components:

Mometasone:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster lung cells
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: positive

Test Type: Mouse Lymphoma
Result: negative

Genotoxicity in vivo: Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Test Type: Chromosomal aberration
Mometasone Dry Powder Inhaler Formulation

Species: Rat
Cell type: Bone marrow
Result: negative

Test Type: unscheduled DNA synthesis assay
Species: Rat
Cell type: Liver cells
Result: negative

Germ cell mutagenicity - Assessment: Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity
Not classified based on available information.

Components:

Mometasone:
Species: Rat
Application Route: Inhalation
Exposure time: 2 Years
Dose: 0.067 mg/kg body weight
Result: negative

Species: Mouse
Application Route: Inhalation
Exposure time: 19 Months
Dose: 0.160 mg/kg body weight
Result: negative

Reproductive toxicity
May damage the unborn child. Suspected of damaging fertility.

Components:

Mometasone:
Effects on fertility: Test Type: Fertility
Species: Rat
Application Route: Subcutaneous
Fertility: NOAEL: 0.015 mg/kg body weight
Symptoms: Reduced embryonic survival, Reduced foetal weight
Result: No effects on fertility, Effect on reproduction capacity

Effects on foetal development: Test Type: Embryo-foetal development
Species: Mouse
Application Route: Subcutaneous
Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight
Result: Embryotoxic effects, Teratogenicity and developmental toxicity

Test Type: Embryo-foetal development
Species: Rat
**Mometasone Dry Powder Inhaler Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
</table>

**Reproductive toxicity - Assessment:**

- Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight
  - Result: Embryo-foetal toxicity

  *Test Type: Embryo-foetal development*
  *Species: Rabbit*
  *Application Route: Dermal*
  *Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight*
  *Result: Embryo-foetal toxicity, Malformations were observed.*

  *Test Type: Embryo-foetal development*
  *Species: Rat*
  *Application Route: Subcutaneous*
  *Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight*
  *Result: Effects on newborn*

  *Test Type: Embryo-foetal development*
  *Species: Rabbit*
  *Application Route: Oral*
  *Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight*
  *Result: Embryo-foetal toxicity, Malformations were observed.*

**STOT - single exposure**

Not classified based on available information.

**Components:**

**Mometasone:**

**Remarks:** Based on available data, the classification criteria are not met.

**STOT - repeated exposure**

May cause damage to organs through prolonged or repeated exposure.

**Components:**

**Mometasone:**

- **Exposure routes:** inhalation (dust/mist/fume)
- **Target Organs:** Immune system, Liver, Kidney, Skin
- **Assessment:** May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity**

**Components:**

**Mometasone:**

- **Species:** Rat
  - **NOAEL:** 0.005 mg/kg
  - **LOAEL:** 0.3 mg/kg
Mometasone Dry Powder Inhaler Formulation

Application Route: Oral
Exposure time: 30 d
Target Organs: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland
Species: Dog
LOAEL: 0.5 mg/kg
Application Route: Oral
Exposure time: 30 d
Target Organs: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland
Species: Rat
NOAEL: 0.00013 mg/l
Application Route: Inhalation (dust/mist/fume)
Exposure time: 90 d
Target Organs: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland
Species: Dog
NOAEL: 0.0005 mg/l
Application Route: Inhalation (dust/mist/fume)
Exposure time: 90 d
Target Organs: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

Aspiration toxicity
Not classified based on available information.

Components:
Mometasone:
Not applicable

Experience with human exposure

Components:
Mometasone:
Inhalation: Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion
Skin contact: Symptoms: Dermatitis, Itching

Further information

Components:
Mometasone:
Remarks: Dermal absorption possible
SECTION 12: Ecological information

12.1 Toxicity

Components:

**Mometasone**

Toxicity to fish:
- LC50 (Menidia beryllina (Silverside)): 0.11 mg/l
  - Exposure time: 96 h
  - Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates:
- EC50 (Daphnia magna (Water flea)): > 5 mg/l
  - Exposure time: 48 h
  - Method: OECD Test Guideline 202
  - Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants:
- EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201
  - Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms:
- EC50: > 1,000 mg/l
  - Exposure time: 3 h
  - Test Type: Respiration inhibition
  - Method: OECD Test Guideline 209
  - Remarks: No toxicity at the limit of solubility

NOEC: 1,000 mg/l
- Exposure time: 3 h
- Test Type: Respiration inhibition
- Method: OECD Test Guideline 209
- Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity):
- NOEC: 0.00014 mg/l
  - Exposure time: 32 d
  - Species: Pimephales promelas (fathead minnow)
  - Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
- NOEC: 0.34 mg/l
  - Exposure time: 21 d
  - Species: Daphnia magna (Water flea)
  - Method: OECD Test Guideline 211
  - Remarks: No toxicity at the limit of solubility
12.2 Persistence and degradability

**Components:**

**Mometasone:**

- **Biodegradability:** Result: Not readily biodegradable. Biodegradation: 50% Exposure time: 28 d Method: OECD Test Guideline 314

- **Stability in water:** Hydrolysis: 50% (12 d) Method: OECD Test Guideline 111

12.3 Bioaccumulative potential

**Components:**

**Mometasone:**

- **Bioaccumulation:** Species: Lepomis macrochirus (Bluegill sunfish) Bioconcentration factor (BCF): 107.1 Method: OECD Test Guideline 305

- **Partition coefficient: n-octanol/water:** log Pow: 4.68

12.4 Mobility in soil

**Components:**

**Mometasone:**

- **Distribution among environmental compartments:** log Koc: 4.02

12.5 Results of PBT and vPvB assessment

Not relevant

12.6 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

**Product:** Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

**Contaminated packaging:** Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Mometasone Dry Powder Inhaler Formulation

SECTION 14: Transport information

14.1 UN number

ADN : UN 3077
ADR : UN 3077
RID : UN 3077
IMDG : UN 3077
IATA : UN 3077

14.2 UN proper shipping name

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
IATA : Environmentally hazardous substance, solid, n.o.s. (Mometasone)

14.3 Transport hazard class(es)

ADN : 9
ADR : 9
RID : 9
IMDG : 9
IATA : 9

14.4 Packing group

ADN
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

ADR
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)
SAFETY DATA SHEET  
according to Regulation (EC) No. 1907/2006

Mometasone Dry Powder Inhaler Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
</table>

**RID**
- Packing group: III
- Classification Code: M7
- Hazard Identification Number: 90
- Labels: 9

**IMDG**
- Packing group: III
- Labels: 9
- EmS Code: F-A, S-F

**IATA (Cargo)**
- Packing instruction (cargo aircraft): 956
- Packing instruction (LQ): Y956
- Packing group: III
- Labels: Miscellaneous

**IATA (Passenger)**
- Packing instruction (passenger aircraft): 956
- Packing instruction (LQ): Y956
- Packing group: III
- Labels: Miscellaneous

### 14.5 Environmental hazards

**ADN**  
Environmentally hazardous: yes

**ADR**  
Environmentally hazardous: yes

**RID**  
Environmentally hazardous: yes

**IMDG**  
Marine pollutant: yes

**IATA (Passenger)**  
Environmentally hazardous: yes

**IATA (Cargo)**  
Environmentally hazardous: yes

### 14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

### 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks: Not applicable for product as supplied.

### SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture
SAFETY DATA SHEET  
according to Regulation (EC) No. 1907/2006

Mometasone Dry Powder Inhaler Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.2</td>
<td>09/13/2019</td>
<td>493905-00010</td>
<td>24.04.2019</td>
</tr>
</tbody>
</table>

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59): Not applicable
REACH - List of substances subject to authorisation (Annex XIV): Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer: Not applicable
Regulation (EC) No 850/2004 on persistent organic pollutants: Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals: Not applicable
REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII): Not applicable

<table>
<thead>
<tr>
<th>E1</th>
<th>ENVIRONMENTAL HAZARDS</th>
<th>Quantity 1</th>
<th>Quantity 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>100 t</td>
<td>200 t</td>
<td></td>
</tr>
</tbody>
</table>

Other regulations:
Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.
Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:
AICS: not determined
DSL: not determined
IECSC: not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements
H360Df: May damage the unborn child. Suspected of damaging fertility.
H373: May cause damage to organs through prolonged or repeated exposure if inhaled.
H410: Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations
Aquatic Chronic: Long-term (chronic) aquatic hazard
Repr.: Reproductive toxicity
STOT RE: Specific target organ toxicity - repeated exposure
Mometasone Dry Powder Inhaler Formulation


Date of first issue: 28.01.2016
Date of last issue: 24.04.2019
Date of revision: 09/13/2019

Version 2.2
SDS Number: 493905-00010

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Classification of the mixture:
Repr. 1B H360Df Calculation method
STOT RE 2 H373 Calculation method
Aquatic Chronic 1 H410 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text.

Material users should review the information and recommendations in the specific context of their
intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

GB / EN